Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means.
(a) What would you do in such a situation? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?
Approach · directive: “what / examine / how”
What it asks · Decide what to do when colleagues propose data manipulation, skipping informed consent and using a rival's patented compounds; weigh options; show how data and drug ethics protect humanity.
It asks 3 things — answer each
- (a) State what you would do in Dr Srinivasan's situation
- (b) Examine each option and its consequences against the ethical questions at stake
- (c) Explain how data ethics and drug ethics can save humanity at large in such a scenario
Open with · The crux as a value conflict, commercial speed versus scientific integrity and patient safety: only a safe, effective drug saves lives, and falsified data harms the people it should protect.
Cover
- Stakeholders, and ethical questions as value conflicts: integrity vs urgency, autonomy vs expedience, honest vs selective reporting, intellectual property vs appropriation.
- (a) Refuse the shortcuts and record objections; use the NDCT Rules 2019's accelerated approval; keep written consent; license the rival's compounds; escalate if overruled.
- (b) Options table (comply, resign silently, reform from within) with consequences; Ranbaxy's 2013 guilty plea and $500 million settlement, exposed by whistle-blower Dinesh Thakur.
- (c) Honest data, the Nuremberg Code's consent rule, lawful access (Natco's compulsory licence for Nexavar) and public trust.
- Systemic safeguards: an independent data-monitoring board, locked audit trails, a protected whistle-blower channel and ethics training.
Close with · Integrity as the fastest route to a cure that lasts: ethics protects patients today and the credibility of science tomorrow.
Add value (verified)
- India's New Drugs and Clinical Trials Rules, 2019 require written informed consent from every trial subject.CDSCO — New Drugs and Clinical Trials Rules, 2019 ↗“In all trials, a freely given, informed, written consent is required to be obtained from each study subject.”
- The New Drugs and Clinical Trials Rules, 2019 allow an accelerated approval process for a new drug, taking into account the disease's severity, rarity or prevalence and the availability or lack of alternative treatments, provided there is a prima facie case of meaningful therapeutic benefit over the existing treatment — a lawful fast track.CDSCO — New Drugs and Clinical Trials Rules, 2019 ↗“Accelerated approval process may be allowed to a new drug for a disease or condition, taking into account its severity, rarity, or prevalence and the availability or lack of alternative treatments, provided that there is a prima facie case of the product being of meaningful therapeutic benefit over the existing treatment”
- Ranbaxy USA pleaded guilty (13 May 2013) to felony charges over adulterated drugs made at two plants in India and agreed to pay $500 million, the largest drug safety settlement to date with a generic drug maker.Generic drug manufacturer Ranbaxy pleads guilty and agrees to pay $500 million — HHS Office of Inspector General (US DOJ announcement, 13 May 2013) ↗“In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty today to felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy's manufacturing facilities in India”
- The Nuremberg Code's first principle: the voluntary consent of the human subject is absolutely essential.Nuremberg Code: Directives for Human Experimentation — Office of Research Integrity, US HHS ↗“The voluntary consent of the human subject is absolutely essential. The experiment should be such as to yield fruitful results for the good of society.”
- Natco obtained a compulsory licence from India's Controller of Patents for Bayer's patented cancer drug Nexavar (sorafenib), with a 6% royalty on net sales to Bayer; the appellate board upheld it.Bayer Corporation v. Union of India and others (IPAB) — WIPO Lex ↗“The third Respondent applied for compulsory license in July 2011, stating that the high price of the cancer treatment was denying access to most patients in India and that they would be able to lower its price for the Indian public. The compulsory license was granted by the Controller of Patents, with 6% of royalties on net sales to be paid to Bayer.”
- Kant's Humanity Formula: never treat humanity, in oneself or others, as a means only but always as an end in itself.Kant's Moral Philosophy — Stanford Encyclopedia of Philosophy ↗“This formulation states that we should never act in such a way that we treat humanity, whether in ourselves or in others, as a means only but always as an end in itself.”
- Down To Earth (national magazine, 14 May 2013): Ranbaxy whistle-blower Dinesh Thakur, a former director, said he found falsified drug data and cGMP violations, notified management, and alerted health authorities when it failed to correct the problems.Ranbaxy to pay $500 million to settle cases in US — Down To Earth (national news magazine), 14 May 2013 ↗“I discovered that the company falsified drug data and systemically violated current good manufacturing practices and good laboratory practices. Ranbaxy’s management was notified of these widespread problems. When they failed to correct the problems, it left me with no choice but to alert healthcare authorities”
Question: UPSC's CS (Main) 2024, GS Paper IV — paper ↗. Approach: Minimalist IAS, checked 1 Oct 2026 (how we verify) — UPSC publishes no model answers. ·
Model answer· 375words · Minimalist IAS
Commercial speed versus scientific integrity and patient safety: in an epidemic only a safe, effective drug saves lives; falsified data harms the very people it should protect.
Stakeholders and ethical questions
- Stakeholders: trial participants and future patients; the health system; regulators; the company and its staff; the research team; the rival patent-holder.
- Questions: integrity versus commercial urgency; participant autonomy versus expedience; honest reporting versus selective disclosure; intellectual property versus appropriation.
(a) What I would do
- Immediately: refuse all three shortcuts in the meeting and record my objections, with their legal and reputational risks, in writing.
- Lawful fast track: the New Drugs and Clinical Trials Rules, 2019 allow accelerated approval, weighing a disease's severity and the availability of alternatives, given a prima facie case of meaningful benefit.
- Consent and licensing: written informed consent stays non-negotiable, as the Rules require; license or collaborate for the rival's compounds.
- If overruled: escalate to the ethics committee and the regulator, and resign rather than sign.
(b) Options and their consequences
| Option | Consequence | Ethical verdict |
|---|---|---|
| Comply | First to market; fraud, harm, liability | Gain bought by wrong means |
| Resign silently | Clean hands; fraud proceeds | Abdication of duty |
| Reform from within | Later, but a trusted drug | Integrity with results |
- The cost of fraud: in 2013 Ranbaxy's US arm pleaded guilty to felony charges over adulterated drugs from two Indian plants and agreed to pay $500 million; a former director, Dinesh Thakur, had alerted health authorities when management failed to correct falsified data.
(c) How data ethics and drug ethics save humanity
- Honest data: complete results let regulators judge true risk and benefit; suppressed negatives return as deaths, recalls and lost faith.
- Consent: the Nuremberg Code opens, 'The voluntary consent of the human subject is absolutely essential.'
- Access with fairness: patents sustain innovation, yet the law offers routes to access; Natco won a compulsory licence for Bayer's cancer drug Nexavar, paying a 6% royalty.
- Public trust: transparent trials win acceptance for a new drug or vaccine in a crisis; lost trust costs more lives than delay.
Systemic safeguards
- Prevent recurrence: an independent data-monitoring board, locked audit trails, a protected whistle-blower channel and ethics training.
Integrity is the fastest route to a cure that lasts; ethics protects patients today and the credibility of science tomorrow.
Prepared by Minimalist IAS to the answer standard of Shivam Singh (mentor, 7 years) · facts checked against official sources (how we verify) · updated 1 Oct 2026. UPSC publishes no model answers: compare your structure and coverage with this, then write your own.
